COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders\n\n\n\n\n TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) --\n \n COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the “AGSM”) held today.\n \n\n\n Results of the AGSM\n \n\n\n The results of the vote in respect of the election of directors of the Company are set out below:\n \n\n\n\n\n Name of Nominee\n \n\n\n\n\n\n\n\n Votes For\n \n\n\n\n\n\n\n\n\n\n\n\n % For\n \n\n\n\n\n\n\n\n\n\n\n\n Votes Against\n \n\n\n\n\n\n\n\n\n\n\n\n % Against\n \n\n\n\n\n\n\n\n\n Peter H. Puccetti (Chair)\n \n\n\n\n\n\n\n\n\n\n\n 580,289\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n 88.92\n \n\n\n\n %\n \n\n\n\n\n\n\n\n\n\n\n\n 72,286\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n 11.08\n \n\n\n\n %\n \n\n\n\n\n Anthony J. Giovinazzo\n \n\n\n\n\n\n 574,954\n \n\n\n\n\n\n\n\n\n\n\n\n\n 88.11\n \n\n\n\n %\n \n\n\n\n\n\n\n 77,621\n \n\n\n\n\n\n\n\n\n\n\n\n\n 11.89\n \n\n\n\n %\n \n\n\n\n\n Ulrich Kosciessa\n \n\n\n\n\n\n 580,140\n \n\n\n\n\n\n\n\n\n\n\n\n\n 88.90\n \n\n\n\n %\n \n\n\n\n\n\n\n 72,435\n \n\n\n\n\n\n\n\n\n\n\n\n\n 11.10\n \n\n\n\n %\n \n\n\n\n\n Ronald W. Miller\n \n\n\n\n\n\n 448,646\n \n\n\n\n\n\n\n\n\n\n\n\n\n 68.75\n \n\n\n\n %\n \n\n\n\n\n\n\n 203,929\n \n\n\n\n\n\n\n\n\n\n\n\n\n 31.25\n \n\n\n\n %\n \n\n\n\n\n Robert A. Seager\n \n\n\n\n\n\n 580,254\n \n\n\n\n\n\n\n\n\n\n\n\n\n 88.92\n \n\n\n\n %\n \n\n\n\n\n\n\n 72,321\n \n\n\n\n\n\n\n\n\n\n\n\n\n 11.08\n \n\n\n\n %\n \n\n\n\n\n David Spear\n \n\n\n\n\n\n\n\n\n\n\n 580,106\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n 88.89\n \n\n\n\n %\n \n\n\n\n\n\n\n\n\n\n\n\n 72,469\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n 11.11\n \n\n\n\n %\n \n\n\n\n\n In addition, at the AGSM, Deloitte LLP was appointed as the Company’s auditor, and an ordinary resolution re-confirming and approving the Company’s Amended and Restated Shareholder Rights Plan (as described in the management information circular circulated in connection with the AGSM dated June 3, 2025) was approved.\n \n\n The Comp...

More updates from Cosciens Biopharma Inc.